Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1997 1
2003 2
2010 1
2011 1
2012 1
2022 1
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Sandborn WJ, et al. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. N Engl J Med. 2012. PMID: 23075178 Free article. Clinical Trial.
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, Arbonés-Mainar JM, Caballol B, Gisbert JP, Rivero M, Sánchez-Rodríguez E, Arias García L, Gutiérrez Casbas A, Merino O, Márquez L, Laredo V, Martín-Arranz MD, López Serrano P, Riestra Menéndez S, González-Muñoza C, de Castro Parga L, Calvo Moya M, Fuentes-Valenzuela E, Esteve M, Iborra M, Dura Gil M, Barreiro-De Acosta M, Lorente-Poyatos RH, Manceñido N, Calafat M, Rodríguez-Lago I, Guardiola Capo J, Payeras MA, Morales Alvarado VJ, Tardillo C, Bujanda L, Muñoz-Nuñez JF, Ber Nieto Y, Bermejo F, Almela P, Navarro-Llavat M, Martínez Montiel P, Rodríguez Gutiérrez C, Van Domselaar M, Sesé E, Martínez Pérez T, Ricart E, Chaparro M, García MJ, López-Sanromán A, Sicilia B, Orts B, López-García A, Martín-Arranz E, Pérez-Calle JL, de Francisco R, García-Planella E, Domènech E, García-López YS. Casas-Deza D, et al. Among authors: riestra menendez s. J Crohns Colitis. 2023 Jan 27;17(1):83-91. doi: 10.1093/ecco-jcc/jjac108. J Crohns Colitis. 2023. PMID: 35913456
Differences between pediatric and adult celiac disease.
Rodrigo-Sáez L, Fuentes-Álvarez D, Pérez-Martínez I, Alvarez-Mieres N, Niño-García P, de-Francisco-García R, Riestra-Menéndez S, Bousoño-García C, Alonso-Arias R, López-Vázquez A. Rodrigo-Sáez L, et al. Among authors: riestra menendez s. Rev Esp Enferm Dig. 2011 May;103(5):238-44. Rev Esp Enferm Dig. 2011. PMID: 21619387 Free article. English, Spanish.
[Esophagitis caused by Candida albicans].
Riestra Menéndez S, Sleiman Halabi H, Suárez González A, Rodrigo Sáez L. Riestra Menéndez S, et al. Rev Esp Enferm Apar Dig. 1989 Aug;76(2):188-93. Rev Esp Enferm Apar Dig. 1989. PMID: 2682835 Review. Spanish.
[Characteristics of patients with familial adenomatous polyposis in Spain. First results of the Spanish Registry of Familial Adenomatous Polyposis].
Alfaro I, Ocaña T, Castells A, Cordero C, Ponce M, Ramón Y Cajal T, Andreu M, Bujanda L, Herráiz M, Hervás Molina AJ, Fernández-Bañares F, Riestra-Menéndez S, Gargallo C, Ruiz A, Bustamante M, Blanco I, Martínez de Juan F; Registro Español de Poliposis Adenomatosa Familiar. Alfaro I, et al. Among authors: riestra menendez s. Med Clin (Barc). 2010 Jun 19;135(3):103-8. doi: 10.1016/j.medcli.2009.09.054. Epub 2010 May 13. Med Clin (Barc). 2010. PMID: 20466390 Spanish.
[Incidence and prevalence of inflammatory bowel disease. Asturian study in 5 areas (EIICEA). Spain].
Saro Gismera C, Riestra Menéndez S, Milla Crespo A, Sánchez Fernández R, Lacort Fernández M, Argüelles Fernández G, Chovac Z, Florido Mancheño JI, Antón Magarzo JL, Altadill Arregui A, Vizoso F, Pineda García E, Fernández de Ocariz Archs E, Albert Colomer J, García Pérez J, López Rivas L, Lombraña JL. Saro Gismera C, et al. Among authors: riestra menendez s. An Med Interna. 2003 Jan;20(1):3-9. An Med Interna. 2003. PMID: 12666301 Spanish.
12 results